Seeking Alpha

barn find

barn find
Send Message
View as an RSS Feed
View barn find's Comments BY TICKER:

Latest  |  Highest rated
  • Anavex: Response To 3 Recent Bearish Articles [View article]
    It does not convince well, when an top bio author alleges "the placebo effect" when in the readily available body of evidence, among the many other studies conducted , slim evidence exists that placebo effect above baseline has occurred in past trials of AD.... I recommend the AF author use google search a bit more before making such statements...
    Nov 16, 2015. 03:40 PM | 5 Likes Like |Link to Comment
  • Anavex: Response To 3 Recent Bearish Articles [View article]
    Funny that some can not understand that when overwhelming evidence exists to be part of a truly earth changing opportunity, that yes it can make some investors excited, attract stock newsletters and promo companies....why is that so hard for some to understand ...duh...
    Nov 16, 2015. 03:34 PM | 5 Likes Like |Link to Comment
  • Anavex Life Sciences: A Promotional Company With Too Many Red Flags [View article]
    Did you notice that almost the entire drop is share price happened in after hours trading and premarket -- i.e. little drop occurred in regular hours of trading.... In case you did not know off hours trading is the time of very low volume....It is funny to hear you and others bash that the stock dropped because of the poor results at CTAD when it is so obvious what actually was the cause of the drop in share price...
    Nov 11, 2015. 12:38 PM | 3 Likes Like |Link to Comment
  • Daniel Ward Failed To Do An Acceptable Level Of Research On His Most Recent Anavex Review [View instapost]
    And yes, the FDA is clearly open to considering new biomarkers to speed drug development. The FDA has a Biomarker Qualification Program:
    Oct 25, 2015. 01:34 PM | Likes Like |Link to Comment
  • Daniel Ward Failed To Do An Acceptable Level Of Research On His Most Recent Anavex Review [View instapost]
    Jeffrey Cummings – Anavex SAB member and also on the JPAD editorial board. He is involved with CTAD however he is not listed along-side the Anavex slot, but will be at various other slots.

    And then there is John Harrison – Worked with the European Task Force, and also on anavex’s SAB and according to and his reputation, he is the cognitive testing guy - also interesting, he is NOT listed in the Anavex slot, nor on anywhere else in Nov 5-7 schedule, yet according to the tweet he put out September 14th as linked below, he will be attending the CTAD conference.

    Now pardon me I am going to another essay again, the science of the trial is not quite fully understood by me and so I been digging around to get a better understanding of it, so please correct me if I am mistaken in what I discuss of my new understanding below, mostly surrounding Dr John Harrison:

    Reading into Harrison, I see that he preaches against the majority of current Alzheimer's tests and measurement methods, stating that they are inadequate. View this webcast linked below, fairly interesting points in it, just need to register a free account first.

    This aired September 20th, topic “Better cognitive measurement for Alzheimer's disease trials.” John Harrison goes in detail regarding Alzheimer’s trials and testing methods. States that MMSE and ADAS-COG tests are inadequate and the industry needs to invest more into better measurement/testing methods. The whole webcast really goes into it for the whole hour. Also, below is a quote from a comment he made on alzforum in March 2015:

    "Established measures such as the DAD and ADCS-ADL have rather shown their age with regard to content, and have been prone to ceiling effects in these early stage patients. "

    So I noticed he is pretty much negative towards all current treatment measures, especially harsh towards ADAS-Cog, and those Anavex is employing now; ADSC-ADL, MMSE. So I started to wonder, what is this doctor doing for Anavex right now? He claims these tests are not valid, not reliable, not adequate, don’t necessarily measure what we need to measure. Mentions that ADSC-ADL is good for detecting big changes in later stages of AD, and not so good for detecting early on-set. But he still would prefer the ADSC over others because he finds it to be FDA-friendly, that it still has a lot of merit but just needs some correlating data to support it. Digging deeper, took long but he finally said it, at the very end of the webcast, at 53:32, that he believes using cognition as a biomarker is the best way of testing and measuring for AD. To bring it back to Anavex: Cognition as a (potential) biomarker = EEG/ERP measuring P300 signal.

    THAT is the reliable, valid test he is constantly preaching about over the other "outdated" tests that are always being used exclusively by other pharmas. What Anavex is presently doing, as shown in the latest date releases, is displaying the P300 Amplitude improvement as the main focus, and showing the correlation of the P300 to the scores of the MMSE and the ADSC-ADL, and in doing so, the P300 test correlation VALIDATES those other tests and makes them a reliable measure.

    For those unfamiliar, here are Anavex's endpoints, from July 22nd press release:

    “Secondary endpoints are dose response, bioavailability, exploratory cognitive effects using electroencephalographic (EEG) activity, including event-related potentials (EEG/ERP), Mini Mental State Examination (MMSE), Cogstate and evaluation of ADSC-ADL and add-on therapy to donepezil”

    And regarding the ADAS-COG, I am mentioning this here because I believe I saw a couple of members discussing this weeks ago, after learning of the complete lack of support of this from Harrison (ADAS-COG, See here for example, his paper from 2007 - , I went looking into the history of when Anavex used that measure.

    ADAS-COG measure was constantly mentioned by Anavex at some point long ago; Dr John Harrison joined the Anavex SAB in December 2013, and the last time ADAS-COG was mentioned by Anavex in a PR was May 2014. Then came the announcement of Phase 2a in August 2014 and in this press release is the first time ADSC-ADL and EEG/ERP measures are both mentioned! Unless I am missing something here, then I am willing to bet that John Harrison has everything to do with the discontinuation of ADAS-COG, and everything to do with the implementation of ADSC-ADL and EEG/ERP measures. And I will say again, EEG/ERP is to measure the cognitive P300 signal, and this is otherwise known as “P300 as a potential biomarker for early detection of conversion from mild cognitive impairment to Alzheimer's dementia” by those others studying it, or as Anavex put it on July 22, “Cognitive EEG/ERP P300 data, a real-time physiological measure of cognitive processes with demonstrated sensitivity to Alzheimer’s disease.”

    This whole thing is important (valuable information as a long term shareholder) because if we are to take John Harrison for his word here and his credentials, we further realize the uniqueness of Anavex and its trials. He has been releasing papers for many years telling that the current standard tests and measure used in trials are NOT valid and NOT reliable, and for MANY years we have been witnesses drug candidate after another fail (for various reasons, but if we take Harrison's word for it, reasons would including using poor biomarkers). Yet here we have him, having implemented new CONGITIVE testing measures, “P300 as a potential biomarker for early detection” and used it to support/correlate to other not so great measures if they were stand-alone, and got rid of outdated and inadequate measures.

    If this is what it took to get a drug tested properly, then maybe this is why our drug might not fail like the rest. It is also why the FDA might view it much more favorably, maybe even contributing to the whole fast-track possibility. Of course I am taking into account that it’s a different approach to treatment all together, however like John says, if you aren’t asking the right questions in the trial, you are not going to get the right answers --- the trials run by Anavex look GREAT , this is a very important aspect to the success of Anavex drug candidates. Bottom-line, Anavex is ahead of the game, will soon prove to be the leader in AD.

    FURTHERMORE, I apologize if this is already *widely* known here but I just stumbled upon this through a link to the FDA website which John Harrison had shared : “Guidance for Industry Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease [draft]” – below is a snippet of a relevant section regarding FDA's support of AD clinical trials that prove disease modification, “Biomarkers as Supportive Secondary Outcome Measures” - they require evidence of both functional AND cognitive improvement. (though again, who knows, maybe there will be fast-track option, maybe phase 3 will set different endpoints.. but as it stands for phase 2, this is the relevant measure; secondary outcome)

    2. Use of Biomarkers as Supportive Secondary Outcome Measures
    We are open to considering the argument that a positive biomarker result (generally included as a secondary outcome measure in a trial) in combination with a positive finding on a primary clinical outcome measure may support a claim of disease modification in AD. For this to be the case, however, there should be widespread evidence-based agreement in the research community that the chosen biomarker reflects a pathophysiologic entity that is fundamental to the underlying disease process. There is currently no consensus as to what particular biomarkers would be appropriate to support clinical findings in trials in early AD. For this reason, we recognize that sponsors at present have insufficient information on which to base a hierarchical structuring of a series of biomarkers as secondary outcome measures in their trial designs. Therefore, we encourage sponsors to analyze the results of these biomarkers independently with the understanding that these findings will be interpreted in the context of the state of the scientific evidence at the time of a future new drug application or biologics license application submission.

    Here is his John Harrison’s profile from

    A member of the Scientific Advisory Board, Dr. Harrison is an internationally acknowledged specialist for design of human clinical outcome measurement in Alzheimer’s disease and other cognitive impairments. Dr. Harrison has successfully integrated cognitive testing into drug development programs for many pharmaceutical and biotechnology companies including eight of the current ‘Fortune’ top 10 pharmaceutical companies. He is Honorary Senior Lecturer in the Department of Medicine at Imperial College in London, focusing on investigating cognitive change that may show disease progression in Alzheimer’s and other related indications. Dr. Harrison is a member of the American Psychological Association, holds Chartered Psychologist status with the British Psychological Society and Chartered Scientist status with the UK Science Council. He has authored/co-authored more than 60 books and scientific articles and has been invited as a specialist for cognitive tests at many international meetings, including the European Task Force for Alzheimer’s disease and American Alzheimer’s Association roundtable events. Dr. Harrison’s background also includes prior positions as Head of Neuropsychology at CeNeS Pharmaceuticals, Principal Consultant at CPC Pharma Services, and Principal Scientist at CogState Ltd. In addition to his current academic appointment, he is principal consultant at Metis Cognition Ltd and holds a PhD in neuroscience from the University of London.
    Oct 25, 2015. 01:29 PM | Likes Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    If you can not provide proof or examples that he scammed, or is a scammer, then you are worse than him..sorry.... and his history of many small failed companies means nothing (although nice try explaining it away this way)... and I read fleecing the lamb when you were in diapers my friend, but this book means nothing about whether you have stepped beyond the bounds of ethical journalism... which you clearly calling this man a scammer with no proof.... and even worse using that mis-information to rattle vulnerable retail... I wonder if you would have done it if he was an American...with full access to the courts....
    Oct 24, 2015. 06:45 PM | Likes Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    BTW it is common for micro-cap companies to be unsuccessful....just because someone trys to start several small companies that do not succeed does not make him a "penny stock scammers" as you so dangerously state....Good journalism requires you to retract these statements by you..
    Oct 24, 2015. 01:20 PM | Likes Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    show proof he is or was a "penny stock scammers" as you directly say or retract your comment ... if you have no proof and can not show it then your level journalism is self explanatory ...also as some advice I think you are opening yourself up to legal liability by stating untruths about individuals...
    Oct 24, 2015. 01:16 PM | Likes Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    very wrong .... he was merely the past president of the shell company that they hired as an admin capacity mainly, sec filings etc... He was later fired which was many years ago BTW .. Even with his minimal involvement give one example of a crime this so called "bad guy" committed...You can not right...funny...You are grossly exaggerating the relevance of this individual to the company...what is wrong with you..
    Oct 21, 2015. 11:55 AM | 1 Like Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    he is also very stubborn thinking to himself "I am too smart to have missed finding this myself and so therefore it can not be good"..
    Oct 20, 2015. 06:38 PM | 5 Likes Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    Anavex 273 was developed by scientists in Greece, Anavex 371 by scientists in Israel .... both are sigma one receptor agonists...These two drugs are the underlying fundamental value of AVXL.... they are AVXL actually.... Your article has attempted to manipulate new and unsure retail investors who do not understand that the years ago previous shell company and past employee (that you give no example of an actual crime he committed) have zero to do with the two drugs developed half way around the world, and which are AVXL now....Shame on you..
    Oct 20, 2015. 01:16 PM | 11 Likes Like |Link to Comment
  • Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech [View article]
    Asolutely nothing new or anything value adding to the known body of info on Anavex... The focus on innuendo and non-material controversy point to a complete lack of understanding of the company and its science..
    Oct 20, 2015. 11:40 AM | 11 Likes Like |Link to Comment
  • Why Anavex Life Sciences' Warrants Will Crush The Stock By 70% Or More [View article]
    The market around this stock was very well aware of the number of warrants outstanding and the terms, and it was talked about many times... My point is that this is all priced in ...and the warrants created some liquidity and a buying opportunity post the very good July 22 trial early data. Without the warrants the stock likely would have gone multiples higher, and almost immediately, after the very positive July 22 news..... In my opinion the warrants have actually helped retail investors by giving them more time to do their DD after the news, and time to accumulate a position...Also while your headline of the "1000%" gain already is headline grabbing, it is diluted market cap compared to similar comparable companies would have been a data point both relevant and useful ...
    Aug 6, 2015. 10:17 AM | 9 Likes Like |Link to Comment
  • You Are Going To Want To Buy Isoray Now [View instapost]
    Any law firm litigating this will be a laughing stock.... get real think about it...ISR told the facts about themselves exactly and if they had decided to talk about the comparatives (other than in the link to the source doc) that could just as easily have been construed as trying to inflate or hype since their results are so much better..... and while targeting a company trying to cure cancer,,,
    May 26, 2015. 09:59 PM | 1 Like Like |Link to Comment
  • You Are Going To Want To Buy Isoray Now [View instapost] distilled it down to the important critical data points...I was amazed over the weekend reading YMB that all most everyone missed these points.... except for one very good post titled something like "AF takes liberties with Peer study" --- if you get a chance go to YMB and read that extended post there from the weekend...
    May 26, 2015. 03:22 PM | 1 Like Like |Link to Comment